- Home
- IMTX vs RLAY Comparison
IMTX vs RLAY Comparison
Compare IMTX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- RLAY
- Stock Information
- Founded
- IMTX N/A
- RLAY 2015
- Country
- IMTX Germany
- RLAY United States
- Employees
- IMTX N/A
- RLAY N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMTX Health Care
- RLAY Health Care
- Exchange
- IMTX Nasdaq
- RLAY Nasdaq
- Market Cap
- IMTX 653.9M
- RLAY 619.0M
- IPO Year
- IMTX N/A
- RLAY 2020
- Fundamental
- Price
- IMTX $6.26
- RLAY $4.12
- Analyst Decision
- IMTX Strong Buy
- RLAY Strong Buy
- Analyst Count
- IMTX 4
- RLAY 13
- Target Price
- IMTX $14.67
- RLAY $18.00
- AVG Volume (30 Days)
- IMTX 984.5K
- RLAY 1.5M
- Earning Date
- IMTX 08-13-2025
- RLAY 11-05-2025
- Dividend Yield
- IMTX N/A
- RLAY N/A
- EPS Growth
- IMTX N/A
- RLAY N/A
- EPS
- IMTX N/A
- RLAY N/A
- Revenue
- IMTX $152,823,253.00
- RLAY $8,355,000.00
- Revenue This Year
- IMTX N/A
- RLAY $31.55
- Revenue Next Year
- IMTX N/A
- RLAY N/A
- P/E Ratio
- IMTX N/A
- RLAY N/A
- Revenue Growth
- IMTX 83.61
- RLAY N/A
- 52 Week Low
- IMTX $3.30
- RLAY $1.78
- 52 Week High
- IMTX $13.09
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- IMTX 58.89
- RLAY 65.83
- Support Level
- IMTX $5.29
- RLAY $3.52
- Resistance Level
- IMTX $5.56
- RLAY $4.26
- Average True Range (ATR)
- IMTX 0.35
- RLAY 0.22
- MACD
- IMTX 0.04
- RLAY 0.07
- Stochastic Oscillator
- IMTX 85.03
- RLAY 85.26
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).